CoChat

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

Open access
Rokita, Jo Lynne, Rathi, Komal S., Cardenas, Maria F., Upton, Kristen A., Jayaseelan, Joy, Cross, Katherine L., Pfeil, Jacob, Egolf, Laura E., Way, Gregory P., Farrel, Alvin, Kendsersky, Nathan M., Patel, Khushbu, Gaonkar, Krutika S., Modi, Apexa, Berko, Esther R., Lopez, Gonzalo, Vaksman, Zalman, Mayoh, Chelsea, Nance, Jonas, McCoy, Kristyn, Haber, Michelle, Evans, Kathryn, McCalmont, Hannah, Bendak, Katerina, Böhm, Julia W., Marshall, Glenn M., Tyrrell, Vanessa, Kalletla, Karthik, Braun, Frank K., Qi, Lin, Du, Yunchen, Zhang, Huiyuan, Lindsay, Holly B., Zhao, Sibo, Shu, Jack, Baxter, Patricia, Morton, Christopher, Kurmashev, Dias, Zheng, Siyuan, Chen, Yidong, Bowen, Jay, Bryan, Anthony C., Leraas, Kristen M., Coppens, Sara E., Doddapaneni, HarshaVardhan, Momin, Zeineen, Zhang, Wendong, Sacks, Gregory I., Hart, Lori S., Krytska, Kateryna, Mosse, Yael P., Gatto, Gregory J., Sanchez, Yolanda, Greene, Casey S., Diskin, Sharon J., Vaske, Olena Morozova, Haussler, David, Gastier-Foster, Julie M., Kolb, E. Anders, Gorlick, Richard, Li, Xiao-Nan, Reynolds, C. Patrick, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A., Lock, Richard B., Raman, Pichai, Wheeler, David A., Maris, John M. · 2019 · Cell Reports
Cited by 173

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and limited therapeutic options. To systematically prioritize and rationally test novel agents in preclinical murine models, researchers within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived xenografts (PDXs)-many of which are refractory to current standard-of-care treatments-from high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our understanding of relapsed disease. In addition, we use expression signatures to classify tumors for TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for pediatric oncology drug development and will guide rational clinical trial design for children with cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2019.09.071

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 173

Metadata

Authors
Rokita, J. L., Rathi, K. S., Cardenas, M. F., Upton, K. A., Jayaseelan, J., Cross, K. L., Pfeil, J., Egolf, L. E., Way, G. P., Farrel, A., Kendsersky, N. M., Patel, K., Gaonkar, K. S., Modi, A., Berko, E. R., Lopez, G., Vaksman, Z., Mayoh, C., Nance, J., McCoy, K., Haber, M., Evans, K., McCalmont, H., Bendak, K., Böhm, J. W., Marshall, G. M., Tyrrell, V., Kalletla, K., Braun, F. K., Qi, L., Du, Y., Zhang, H., Lindsay, H. B., Zhao, S., Shu, J., Baxter, P., Morton, C., Kurmashev, D., Zheng, S., Chen, Y., Bowen, J., Bryan, A. C., Leraas, K. M., Coppens, S. E., Doddapaneni, H., Momin, Z., Zhang, W., Sacks, G. I., Hart, L. S., Krytska, K., Mosse, Y. P., Gatto, G. J., Sanchez, Y., Greene, C. S., Diskin, S. J., Vaske, O. M., Haussler, D., Gastier-Foster, J. M., Kolb, E. A., Gorlick, R., Li, X.-N., Reynolds, C. P., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., Lock, R. B., Raman, P., Wheeler, D. A., & Maris, J. M.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2019-11
Volume
29
Issue
6
Pages
1675-1689.e9
ISSN
2211-1247 (ISSN-L)
OpenAlex
W2986723641
Cited by
173
References
21
FWCI
6.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.